Rituximab

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Granulomatosis With Polyangiitis (Wegener's Granulomatosis)

Conditions

Granulomatosis With Polyangiitis (Wegener's Granulomatosis)

Trial Timeline

Dec 1, 2015 → Jul 1, 2017

NCT ID

NCT02626845

About Rituximab

Rituximab is a approved stage product being developed by Roche for Granulomatosis With Polyangiitis (Wegener's Granulomatosis). The current trial status is terminated. This product is registered under clinical trial identifier NCT02626845. Target conditions include Granulomatosis With Polyangiitis (Wegener's Granulomatosis).

What happened to similar drugs?

1 of 3 similar drugs in Granulomatosis With Polyangiitis (Wegener's Granulomatosis) were approved

Approved (1) Terminated (0) Active (2)

✅Methylprednisolone + Prednisone + RituximabRocheApproved

🔄BenralizumabAstraZenecaPhase 3

🔄Abatacept + placeboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02654379	Pre-clinical	Completed	Dec 18, 2015	Sep 29, 2017	Off-Label Use
NCT02626845	Approved	Terminated	Dec 1, 2015	Jul 1, 2017	Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
NCT01987505	Phase 3	Completed	Nov 11, 2013	Apr 11, 2017	Lymphoma, Non Hodgkin
NCT01750697	Phase 2	Completed	May 23, 2013	May 10, 2018	Granulomatosis With Polyangiitis
NCT01684865	Pre-clinical	Completed	Oct 22, 2012	Nov 27, 2017	Non-Hodgkin's Lymphoma
NCT01609023	Pre-clinical	Completed	Apr 1, 2012	Nov 1, 2015	Lymphocytic Leukemia, Chronic
NCT01613027	Pre-clinical	Completed	Feb 1, 2012	Sep 1, 2015	Rheumatoid Arthritis
NCT01641952	Pre-clinical	Completed	Oct 1, 2011	Jan 1, 2015	Rheumatoid Arthritis
NCT01066598	Phase 2	Terminated	May 1, 2010	Aug 1, 2011	Graft Versus Host Disease
NCT01178086	Pre-clinical	Completed	Feb 22, 2010	Jun 30, 2015	Lymphocytic Leukemia, Chronic
NCT01071798	Pre-clinical	Completed	Jan 1, 2010	Oct 1, 2014	Rheumatoid Arthritis
NCT01118234	Phase 3	Completed	Dec 1, 2009	Jul 1, 2019	Chronic Lymphocytic Leukemia
NCT02536664	Pre-clinical	Completed	Sep 1, 2009	Jun 1, 2014	Follicular Lymphoma
NCT02461290	Pre-clinical	Completed	Apr 1, 2008	Nov 1, 2013	Follicular Lymphoma
NCT02622503	Pre-clinical	Completed	Apr 1, 2008	Aug 1, 2008	Rheumatoid Arthritis
NCT00509184	Phase 2	Completed	Mar 1, 2008	Apr 1, 2013	Lymphoma, Malignant
NCT00774462	Phase 2	Completed	Jan 1, 2008	Dec 1, 2011	Myositis
NCT00531089	Phase 2	UNKNOWN	Dec 1, 2007	Jan 1, 2011	Thrombotic Thrombocytopenic Purpura
NCT00963703	Pre-clinical	Completed	Dec 1, 2007	Mar 1, 2012	Rheumatoid Arthritis
NCT00645606	Phase 3	Completed	Dec 1, 2007	Jul 1, 2017	Leukemia

Competing Products

9 competing products in Granulomatosis With Polyangiitis (Wegener's Granulomatosis)

See all competitors

Product	Company	Stage	Hype Score
NS-229 + Placebo	Nippon Shinyaku	Phase 2	42
Benralizumab	AstraZeneca	Phase 3	47
Tezepelumab + Placebo	AstraZeneca	Phase 2	42
Rituximab	Roche	Phase 2	35
Methylprednisolone + Prednisone + Rituximab	Roche	Approved	43
Avacopan + Placebo	Amgen	Phase 2/3	45
Abatacept + placebo	Bristol Myers Squibb	Phase 3	40
IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC)	InflaRx	Phase 2	25
IFX-1 low dose + IFX-1 high dose + Placebo	InflaRx	Phase 2	17